TRICAPITAL Angel Investors

ŌGI Bio is a newly formed start-up company from The University of Edinburgh with the mission to revolutionize the way that microbes are grown and managed.

Carcinotech is focused on treating cancers and is based at the Roslin Innovation Centre on the outskirts of Edinburgh.

Aveni is a video conferencing company that utilizes artificial intelligence and natural language processing to enhance client engagement for financial advisors. Its platform features a GPT-powered AI assistant that automates various tasks, including CRM functions and live risk monitoring. By providing tools for identifying risks and improving compliance, Aveni enables advisors to streamline their operations, increase efficiency, and better serve their clients while meeting regulatory requirements.

Aurum Biosciences Ltd develops pharmaceuticals. The company’s products and technology include Perfluorocarbon which carry oxygen to organs and tissues; Magnetic Resonance Imaging which is a medical imaging technique that does not use ionising radiation and Proprietary image analysis software which provides accurate analyses of images of the stroke patient’s brain. Aurum Biosciences Ltd was founded in 2010 and is headquartered in Glasgow, United Kingdom.

Aveni is a video conferencing company that utilizes artificial intelligence and natural language processing to enhance client engagement for financial advisors. Its platform features a GPT-powered AI assistant that automates various tasks, including CRM functions and live risk monitoring. By providing tools for identifying risks and improving compliance, Aveni enables advisors to streamline their operations, increase efficiency, and better serve their clients while meeting regulatory requirements.

MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, focused on developing a novel class of anti-infective medicines derived from DNA Minor Groove Binders (MGB). Established in 2009, the company is dedicated to creating small molecule antibacterial agents effective against both multi-resistant and susceptible Gram-positive pathogens. One of its key products, MGB-BP-3, is being developed in an oral formulation for the treatment of Clostridium difficile associated disease. By targeting bacteria through a unique mode of action, MGB Biopharma aims to address the challenge of antibiotic resistance, offering healthcare providers more effective treatment options for bacterial infections. The experienced team at MGB Biopharma leverages expertise from the pharmaceutical and biotechnology sectors to drive its innovative research and development efforts.

MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, focused on developing a novel class of anti-infective medicines derived from DNA Minor Groove Binders (MGB). Established in 2009, the company is dedicated to creating small molecule antibacterial agents effective against both multi-resistant and susceptible Gram-positive pathogens. One of its key products, MGB-BP-3, is being developed in an oral formulation for the treatment of Clostridium difficile associated disease. By targeting bacteria through a unique mode of action, MGB Biopharma aims to address the challenge of antibiotic resistance, offering healthcare providers more effective treatment options for bacterial infections. The experienced team at MGB Biopharma leverages expertise from the pharmaceutical and biotechnology sectors to drive its innovative research and development efforts.

Blue Square Utilities Ltd is an independent smart meter installation company based in Newcastle upon Tyne, United Kingdom, serving small to medium-sized energy suppliers across the UK. Established in 2017, the company specializes in the installation and maintenance of both legacy and commercial metering services. Blue Square Utilities provides a comprehensive range of services, including data management, scheduling, customer interaction, asset management, and accredited meter operator and meter asset manager services. The team consists of fully qualified dual fuel smart meter installers, ensuring a high standard of service in the Smart Metering Rollout initiative. Their expertise allows them to deliver an end-to-end dual fuel smart meter installation solution for their clients.

Ryboquin™ uses its expertise to turn under-developed intellectual property ideas into viable commercial realities. Founded in Scotland, Ryboquin Ltd is a privately held, virtual pharmaceutical company focused on commercialising patented technologies in the area of human cancer medicine. Founded in Scotland, Ryboquin is a privately held, virtual pharmaceutical company focused on commercializing patented technologies in the area of human cancer medicine.

MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, focused on developing a novel class of anti-infective medicines derived from DNA Minor Groove Binders (MGB). Established in 2009, the company is dedicated to creating small molecule antibacterial agents effective against both multi-resistant and susceptible Gram-positive pathogens. One of its key products, MGB-BP-3, is being developed in an oral formulation for the treatment of Clostridium difficile associated disease. By targeting bacteria through a unique mode of action, MGB Biopharma aims to address the challenge of antibiotic resistance, offering healthcare providers more effective treatment options for bacterial infections. The experienced team at MGB Biopharma leverages expertise from the pharmaceutical and biotechnology sectors to drive its innovative research and development efforts.

FINDRA is a Scottish brand specializing in high-performance outdoor and adventure clothing for women. The company focuses on designing stylish and versatile apparel made from sustainable materials, including Italian sports merino wool, known for its natural wicking properties. FINDRA aims to inspire women to embrace an active and healthy lifestyle, enabling them to pursue outdoor adventures without sacrificing performance or style. Through its e-commerce platform, FINDRA encourages consumers to engage with nature and enhances their experience by providing functional yet fashionable clothing options.

My1Login Limited is a cloud-based password management and identity access management company headquartered in Glasgow, United Kingdom, with additional offices in Palo Alto, California, and London. Founded in 2007, My1Login offers a secure vault that allows users to manage their passwords and online bookmarks while securely encrypting and storing sensitive personal information, such as bank details and emergency contacts. The company specializes in addressing enterprise cybersecurity threats through its advanced Identity and Access Management (IAM) solutions, which provide a unified user identity for employees. This approach improves productivity and enhances security by addressing issues like identity sprawl and password fatigue. My1Login's IAM platform supports various identity standards, including SAML and OAuth 2.0, and can integrate with legacy systems, ensuring comprehensive protection across cloud, mobile, and desktop applications. Their solutions can be rapidly deployed, even in complex enterprise environments, delivering compliance and a measurable return on investment.

Aurum Biosciences Ltd develops pharmaceuticals. The company’s products and technology include Perfluorocarbon which carry oxygen to organs and tissues; Magnetic Resonance Imaging which is a medical imaging technique that does not use ionising radiation and Proprietary image analysis software which provides accurate analyses of images of the stroke patient’s brain. Aurum Biosciences Ltd was founded in 2010 and is headquartered in Glasgow, United Kingdom.

My1Login Limited is a cloud-based password management and identity access management company headquartered in Glasgow, United Kingdom, with additional offices in Palo Alto, California, and London. Founded in 2007, My1Login offers a secure vault that allows users to manage their passwords and online bookmarks while securely encrypting and storing sensitive personal information, such as bank details and emergency contacts. The company specializes in addressing enterprise cybersecurity threats through its advanced Identity and Access Management (IAM) solutions, which provide a unified user identity for employees. This approach improves productivity and enhances security by addressing issues like identity sprawl and password fatigue. My1Login's IAM platform supports various identity standards, including SAML and OAuth 2.0, and can integrate with legacy systems, ensuring comprehensive protection across cloud, mobile, and desktop applications. Their solutions can be rapidly deployed, even in complex enterprise environments, delivering compliance and a measurable return on investment.

Lamellar Biomedical Ltd. is a biotechnology company based in Bellshill, United Kingdom, focused on developing and commercializing medical devices and pharmaceuticals that utilize mimetics of extra-alveolar lamellar bodies. Established in 2006 and renamed in 2007, the company has harnessed the therapeutic potential of its proprietary product, Lamellasomes, a synthetic substance designed to mimic the actions of natural lamellar bodies. These products aim to treat various conditions, including respiratory diseases such as cystic fibrosis, as well as complications from radiotherapy-induced xerostomia and dry eye disease. Lamellar Biomedical is dedicated to advancing innovative therapies to address significant medical needs.

My1Login Limited is a cloud-based password management and identity access management company headquartered in Glasgow, United Kingdom, with additional offices in Palo Alto, California, and London. Founded in 2007, My1Login offers a secure vault that allows users to manage their passwords and online bookmarks while securely encrypting and storing sensitive personal information, such as bank details and emergency contacts. The company specializes in addressing enterprise cybersecurity threats through its advanced Identity and Access Management (IAM) solutions, which provide a unified user identity for employees. This approach improves productivity and enhances security by addressing issues like identity sprawl and password fatigue. My1Login's IAM platform supports various identity standards, including SAML and OAuth 2.0, and can integrate with legacy systems, ensuring comprehensive protection across cloud, mobile, and desktop applications. Their solutions can be rapidly deployed, even in complex enterprise environments, delivering compliance and a measurable return on investment.

MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, focused on developing a novel class of anti-infective medicines derived from DNA Minor Groove Binders (MGB). Established in 2009, the company is dedicated to creating small molecule antibacterial agents effective against both multi-resistant and susceptible Gram-positive pathogens. One of its key products, MGB-BP-3, is being developed in an oral formulation for the treatment of Clostridium difficile associated disease. By targeting bacteria through a unique mode of action, MGB Biopharma aims to address the challenge of antibiotic resistance, offering healthcare providers more effective treatment options for bacterial infections. The experienced team at MGB Biopharma leverages expertise from the pharmaceutical and biotechnology sectors to drive its innovative research and development efforts.

Fios Genomics Ltd., founded in 2008 as a spinout from the University of Edinburgh, offers comprehensive bioinformatics data analysis services to the pharmaceutical industry, biotechnology firms, contract research organizations, and academic institutions globally. The company specializes in a variety of analytical services, including microarray analysis, next-generation sequencing, and agricultural genomics. Fios Genomics also provides proteomic and metabolomic services, facilitating biomarker identification, protein profiling, and metabolite analysis. Additionally, the firm offers consultancy services covering technology selection, experimental design, and data interpretation. Its expertise extends to supporting pre-clinical and clinical development, drug repurposing, and stratified medicine applications, thereby enabling clients to leverage genomic, transcriptomic, proteomic, and metabolomic data effectively. Based in Edinburgh, Fios Genomics serves a diverse clientele across the UK, US, EU, and Asia.

Ryboquin™ uses its expertise to turn under-developed intellectual property ideas into viable commercial realities. Founded in Scotland, Ryboquin Ltd is a privately held, virtual pharmaceutical company focused on commercialising patented technologies in the area of human cancer medicine. Founded in Scotland, Ryboquin is a privately held, virtual pharmaceutical company focused on commercializing patented technologies in the area of human cancer medicine.

Fios Genomics Ltd., founded in 2008 as a spinout from the University of Edinburgh, offers comprehensive bioinformatics data analysis services to the pharmaceutical industry, biotechnology firms, contract research organizations, and academic institutions globally. The company specializes in a variety of analytical services, including microarray analysis, next-generation sequencing, and agricultural genomics. Fios Genomics also provides proteomic and metabolomic services, facilitating biomarker identification, protein profiling, and metabolite analysis. Additionally, the firm offers consultancy services covering technology selection, experimental design, and data interpretation. Its expertise extends to supporting pre-clinical and clinical development, drug repurposing, and stratified medicine applications, thereby enabling clients to leverage genomic, transcriptomic, proteomic, and metabolomic data effectively. Based in Edinburgh, Fios Genomics serves a diverse clientele across the UK, US, EU, and Asia.

The complexity and breadth of online media has reached a level where it is virtually impossible to manage your online marketing without clever software to help you. 4th aspect provides marketing professionals with tools that: measure, optimize and promote your content in virtually any form, across multiple content platforms and allows your marketing team to engage with advocates, influencers and of course customers. 4th aspect frees up your marketing resources and allows your team to create the content that your audience really cares about. Promote your brand on a global scale, while reducing costs and increasing control. Place your Brand ahead of your competitors and in front of your customers!

My1Login Limited is a cloud-based password management and identity access management company headquartered in Glasgow, United Kingdom, with additional offices in Palo Alto, California, and London. Founded in 2007, My1Login offers a secure vault that allows users to manage their passwords and online bookmarks while securely encrypting and storing sensitive personal information, such as bank details and emergency contacts. The company specializes in addressing enterprise cybersecurity threats through its advanced Identity and Access Management (IAM) solutions, which provide a unified user identity for employees. This approach improves productivity and enhances security by addressing issues like identity sprawl and password fatigue. My1Login's IAM platform supports various identity standards, including SAML and OAuth 2.0, and can integrate with legacy systems, ensuring comprehensive protection across cloud, mobile, and desktop applications. Their solutions can be rapidly deployed, even in complex enterprise environments, delivering compliance and a measurable return on investment.

Smart Compliance Ltd was established in 2010 by directors Scott Wallace and Billy Mitchell to develop a detector incorporating the ability to communicate and store data externally. It enables landlords to ensure appliance safety without having to gain access to a property, and ensures compliance with health and safety standards and legislation.

Inquisitive Systems Ltd., founded in 2008 and based in Edinburgh, United Kingdom, specializes in developing data protection software aimed at safeguarding intellectual property from security breaches. The company’s flagship product, foxDNATM, originated from a postgraduate project by co-founder Dr. Jamie Graves and has evolved into a comprehensive solution that examines relevant data, provides alerts, and monitors forensic user activity. After initiating commercial trading in 2010, Inquisitive Systems has positioned itself as an ambitious contender in the information security software market, leveraging its strong academic roots as a spin-out from Edinburgh Napier University. The company aims to establish itself as a global leader in this space.

Lamellar Biomedical Ltd. is a biotechnology company based in Bellshill, United Kingdom, focused on developing and commercializing medical devices and pharmaceuticals that utilize mimetics of extra-alveolar lamellar bodies. Established in 2006 and renamed in 2007, the company has harnessed the therapeutic potential of its proprietary product, Lamellasomes, a synthetic substance designed to mimic the actions of natural lamellar bodies. These products aim to treat various conditions, including respiratory diseases such as cystic fibrosis, as well as complications from radiotherapy-induced xerostomia and dry eye disease. Lamellar Biomedical is dedicated to advancing innovative therapies to address significant medical needs.

pureLiFi Ltd. is a technology company based in Edinburgh, UK, specializing in light communication solutions through its innovative Li-Fi technology. This technology utilizes visible light spectrum instead of traditional radio frequencies for wireless data communication, addressing the growing demand for bandwidth. The company's product offerings include Li-1st for developing VLC applications, Li-Flame for secure wireless networking, and the Li-Fire Platform for enhanced communication using visible light. Additionally, pureLiFi provides devices like LiFi-XC, which includes access points and USB dongles, ensuring compatibility with various operating systems. The applications of pureLiFi's technology span several sectors, including healthcare, aviation, and transportation, enabling high-density data transfer while minimizing external network interference. Founded in 2012, pureLiFi was previously known as pureVLC Ltd. before rebranding in 2013.

Blackford Analysis Ltd. specializes in software solutions that enhance the comparison of medical images, thereby improving efficiency and productivity in healthcare settings. The company's key offerings include the Blackford Workflow Server, which integrates seamlessly into hospital IT systems to facilitate image pre-processing, and the Blackford Smart Localizer, designed for easy comparison of multiple imaging studies within the Philips IntelliSpace PACS interface. Furthermore, Blackford Custom Solutions provides libraries that support the Workflow Server, while the company also develops tailored image processing capabilities for various clients, including radiologists and healthcare enterprises. Founded in 2010 as a spin-out from the University of Edinburgh, Blackford Analysis has established partnerships with leading imaging system providers and has expanded its presence with sales offices in the UK and the USA. Through its innovative products, the company aims to save clinicians time and enhance communication across healthcare enterprises.

Syntropharma Limited is a pharmaceutical company based in Melrose, United Kingdom, founded in 2005. The company specializes in the production and distribution of skin patches that deliver proven medicines for various diseases, particularly targeting neurological conditions such as Alzheimer's disease and depression. Syntropharma focuses on reformulating commercially successful generic compounds into transdermal applications, aiming to enhance their clinical profiles. With a vision to develop innovative first and second-to-market products, the company intends to establish strong intellectual property and subsequently out-license these products to pharmaceutical partners.

Fios Genomics Ltd., founded in 2008 as a spinout from the University of Edinburgh, offers comprehensive bioinformatics data analysis services to the pharmaceutical industry, biotechnology firms, contract research organizations, and academic institutions globally. The company specializes in a variety of analytical services, including microarray analysis, next-generation sequencing, and agricultural genomics. Fios Genomics also provides proteomic and metabolomic services, facilitating biomarker identification, protein profiling, and metabolite analysis. Additionally, the firm offers consultancy services covering technology selection, experimental design, and data interpretation. Its expertise extends to supporting pre-clinical and clinical development, drug repurposing, and stratified medicine applications, thereby enabling clients to leverage genomic, transcriptomic, proteomic, and metabolomic data effectively. Based in Edinburgh, Fios Genomics serves a diverse clientele across the UK, US, EU, and Asia.

designLED is an internationally recognized company specializing in LED lighting systems and technology, primarily serving the automotive industry. Founded in 2004, the company focuses on designing and developing innovative lighting and human-machine interface (HMI) products that meet the growing global demand for low-energy and cost-effective lighting solutions. Their offerings include customizable optics integrated with flexible light tiles, allowing for versatility in applications such as directional lighting and backlighting. By leveraging advanced technologies and strategic partnerships, designLED aims to transform lighting products and enhance their functionality in diverse environments, aligning with global trends and regulations that prioritize energy efficiency and sustainability.

Sphinx Medical Ltd. is a company located in Bellshill, Scotland, United Kingdom. It develops the artificial sphincter Flow-Secure, which has been sold in Europe for 9 years. It is an innovative device that enables the treatment of severe Male Urinary Incontinence.

IRT Surveys Limited is a UK-based company that specializes in infrared thermal imaging for the non-destructive testing and diagnosis of building defects and energy inefficiencies. Founded in 2002 and located in Dundee, the company provides a range of services including thermal imaging surveys, energy audits, air leakage detection, and electronic leak detection. Additionally, IRT Surveys offers energy performance certificates and maintenance planning services. Utilizing proprietary software, the company analyzes infrared images to quantify energy loss, enabling clients such as building surveyors and facility managers to make informed decisions regarding energy efficiency and property maintenance. Through its innovative approach, IRT Surveys aims to help clients optimize their budgets and plan effectively for future improvements.

Actual Analytics Limited provides behavior analysis solutions for scientific studies. It offers ActualTrack, a tool for automatically tracking the movement of lab animals on video, such as rodents, drosophila, and zebrafish; and The Actual Home Cage Analysis (ActualHCA), a product that allows for the non-invasive gathering of data alongside automated analysis of the behaviors displayed by group-housed rodents. The company sells its products through distributors in the United States, Spain, Taiwan, China, and Germany. Actual Analytics Limited was incorporated in 2009 and is based in Edinburgh, United Kingdom.

MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, focused on developing a novel class of anti-infective medicines derived from DNA Minor Groove Binders (MGB). Established in 2009, the company is dedicated to creating small molecule antibacterial agents effective against both multi-resistant and susceptible Gram-positive pathogens. One of its key products, MGB-BP-3, is being developed in an oral formulation for the treatment of Clostridium difficile associated disease. By targeting bacteria through a unique mode of action, MGB Biopharma aims to address the challenge of antibiotic resistance, offering healthcare providers more effective treatment options for bacterial infections. The experienced team at MGB Biopharma leverages expertise from the pharmaceutical and biotechnology sectors to drive its innovative research and development efforts.

Syntropharma Limited is a pharmaceutical company based in Melrose, United Kingdom, founded in 2005. The company specializes in the production and distribution of skin patches that deliver proven medicines for various diseases, particularly targeting neurological conditions such as Alzheimer's disease and depression. Syntropharma focuses on reformulating commercially successful generic compounds into transdermal applications, aiming to enhance their clinical profiles. With a vision to develop innovative first and second-to-market products, the company intends to establish strong intellectual property and subsequently out-license these products to pharmaceutical partners.

IRT Surveys Limited is a UK-based company that specializes in infrared thermal imaging for the non-destructive testing and diagnosis of building defects and energy inefficiencies. Founded in 2002 and located in Dundee, the company provides a range of services including thermal imaging surveys, energy audits, air leakage detection, and electronic leak detection. Additionally, IRT Surveys offers energy performance certificates and maintenance planning services. Utilizing proprietary software, the company analyzes infrared images to quantify energy loss, enabling clients such as building surveyors and facility managers to make informed decisions regarding energy efficiency and property maintenance. Through its innovative approach, IRT Surveys aims to help clients optimize their budgets and plan effectively for future improvements.

Antoxis Limited is a pre-clinical drug discovery company based in Aberdeen, United Kingdom, focusing on regenerative medicine and mitochondrial-related diseases. The company employs its patented Kromex chemistry scaffold to develop new chemical entities (NCE) that target various high-value clinical indications. This innovative scaffold is grounded in research on free radical biology and redox chemistry, allowing for the protection and modulation of over 100 million compounds. Antoxis concentrates on Kromex compounds known for their rapid mitochondrial targeting, potent activity, and long-term stability within cells. Its lead drug families include Proxison, which enhances the effectiveness of regenerative medicine therapies and is also being investigated for neurodegenerative diseases, and Oncamex, a mitochondrial redox modulator designed for co-therapy in drug-resistant cancers, demonstrating synergy with existing cancer treatments. Founded in 2005, Antoxis continues to advance its drug discovery efforts with a strong emphasis on addressing oxidative stress and mitochondrial dysfunction.

Exterity specializes in delivering enterprise-class IPTV solutions that enable organizations to distribute broadcast-quality digital TV and video over IP networks. Since its establishment in 2001, the company has expanded its reach to 29 countries, serving over 1,000 customers, including many prominent corporations. Exterity's products are designed to manage and control video content efficiently across a large number of endpoints, ensuring high performance and availability. This capability allows clients to leverage video for various purposes, including communication, education, and entertainment, effectively harnessing the power of digital media within their facilities.

Biopta Ltd. is a contract research organization based in Glasgow, United Kingdom, specializing in human tissue-based services for the pharmaceutical industry. Founded in 2002, the company utilizes ethically donated residual human tissue from surgeries to predict drug activity before clinical trials. Biopta provides a range of services, including laboratory and comparative pharmacology, clinical biopsies, and in-vitro and ex-vivo techniques. Its offerings encompass specialized services related to various physiological areas, such as cardiac, vascular, respiratory, gastrointestinal, and genitourinary functions. Additionally, Biopta maintains a catalogue of human functional tissue assays, featuring a variety of standard assays. The company also has a laboratory in Maryland and operates as a subsidiary of ReproCELL, Inc.

Syntropharma Limited is a pharmaceutical company based in Melrose, United Kingdom, founded in 2005. The company specializes in the production and distribution of skin patches that deliver proven medicines for various diseases, particularly targeting neurological conditions such as Alzheimer's disease and depression. Syntropharma focuses on reformulating commercially successful generic compounds into transdermal applications, aiming to enhance their clinical profiles. With a vision to develop innovative first and second-to-market products, the company intends to establish strong intellectual property and subsequently out-license these products to pharmaceutical partners.

Founded in 2003 by Graeme Bryce and Dave Reynolds, Factonomy licenses its technology framework to companies to help them reduce the time and cost it takes to develop applications. Factonomy's agile software environment enables the rapid development of web-enabled business applications using declarative XML only. Unlike other development platforms, the Factonomy Framework allows developers to work independently on functionality, content and style, providing a coherent end-to-end environment so they can deliver solutions which are flexible and cost effective.

Turnbull & Scott (Engineers) Ltd, a British engineering company formed in 1933, specialise in the generation, transfer and recovery of heat. Our clients include some of the world’s top companies, and we have an unrivalled reputation for building robust, intelligent products for today’s industrial and commercial heating and cooling applications. As highly trained specialist engineers, we enjoy nothing more than a good challenge where we can make a real difference to our clients. Turnbull & Scott heat exchange solutions are all about long life and outstanding performance. Our exceptional design and build quality makes our products particularly suited to harsh environments or inaccessible sites, where long plant life and minimum maintenance are essential. With over 80 years combined experience across the nuclear, food processing, oil and gas, paper and packaging, petrochemical and pharmaceutical industries, as well as countless commercial and public sector clients, we deliver practical heating solutions and technical advice you can trust. We’re proud of our British manufacturing tradition and our highly skilled workforce. As committed Investors in People and partners of the University of Strathclyde, our team continue to develop high-performance heating solutions to meet the challenges of the 21st century.

PowerPhotonic Limited specializes in the manufacture of precision micro-optics for applications in laser projection systems, optical telecommunications, and industrial materials processing. The company designs and fabricates a variety of products, including high-powered diode laser optics, microlens arrays, beam shapers, and beam homogenizers. Additionally, PowerPhotonic offers design and prototyping services tailored to specific customer needs. Founded in 2004 and headquartered in Dalgety Bay, United Kingdom, the company operates globally through a network of distributors, with a notable presence in North America and Southeast Asia. Its innovative solutions, such as beam correction phase plates and application-specific micro-optic arrays, are aimed at improving laser performance and efficiency across various industries.

Antoxis Limited is a pre-clinical drug discovery company based in Aberdeen, United Kingdom, focusing on regenerative medicine and mitochondrial-related diseases. The company employs its patented Kromex chemistry scaffold to develop new chemical entities (NCE) that target various high-value clinical indications. This innovative scaffold is grounded in research on free radical biology and redox chemistry, allowing for the protection and modulation of over 100 million compounds. Antoxis concentrates on Kromex compounds known for their rapid mitochondrial targeting, potent activity, and long-term stability within cells. Its lead drug families include Proxison, which enhances the effectiveness of regenerative medicine therapies and is also being investigated for neurodegenerative diseases, and Oncamex, a mitochondrial redox modulator designed for co-therapy in drug-resistant cancers, demonstrating synergy with existing cancer treatments. Founded in 2005, Antoxis continues to advance its drug discovery efforts with a strong emphasis on addressing oxidative stress and mitochondrial dysfunction.

Touch Bionics Limited, located in Livingston, Scotland, specializes in the development and marketing of advanced upper-limb prosthetics aimed at patients with upper-limb deficiencies. The company's notable products include the i-LIMB Hand, a multi-articulating bionic hand designed to assist amputees, and self-contained powered Prosthetic Digits, which offer functionality for individuals with partial hand loss. Additionally, Touch Bionics provides ProDigits, a solution for patients missing fingers. Their offerings extend to highly realistic passive functional prostheses, which are designed to closely resemble the natural appearance of the wearer. Touch Bionics distributes its innovative products across various regions, including the United States, Europe, Asia, and parts of South America and Africa. Established in 2003, the company was previously known as Touch EMAS Limited and rebranded in 2005. As of 2016, Touch Bionics operates as a subsidiary of Ossur Hf.

Syntropharma Limited is a pharmaceutical company based in Melrose, United Kingdom, founded in 2005. The company specializes in the production and distribution of skin patches that deliver proven medicines for various diseases, particularly targeting neurological conditions such as Alzheimer's disease and depression. Syntropharma focuses on reformulating commercially successful generic compounds into transdermal applications, aiming to enhance their clinical profiles. With a vision to develop innovative first and second-to-market products, the company intends to establish strong intellectual property and subsequently out-license these products to pharmaceutical partners.

Gas Sensing Solutions Ltd. specializes in the manufacture of carbon dioxide (CO2) sensors, utilizing innovative technology for various applications. The company offers several product lines, including the COZIR Ambient sensors designed for building control, horticulture, and educational environments, as well as the COZIR Wide Range sensors suitable for process control in sectors such as diving, industrial safety, and automotive. Additionally, the SprintIR sensor provides high-speed CO2 measurement for analytical instrumentation and metabolic assessment. Established in 2005 and headquartered in Glasgow, United Kingdom, Gas Sensing Solutions also provides tailored hardware and software development services to meet specific client needs.